CLARIANE Aktie

 

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

The world's first blood test designed to help clinicians distinguish unipolar depression from bipolar disorder, myEDIT-B has demonstrated a high level of acceptability and clinical utility to psychiatrists and their patients in a European real-world study. PARIS, Oct. 15, 2025......

The 2025 interim financial report, including the interim management report and the condensed consolidated interim financial statements at 30 June 2025, is available on the company's website www.clariane.com. The condensed interim consolidated financial statements were approved by the Board of Directors at its meeting on 29 July 2025 and were subject to a limited review by the Statutory Auditors. The condensed interim consolidated financial statements have been prepared in accordance with IAS 34. For comparison purposes, the following financial information is presented excluding the application of IFRS 16...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

        ...

        ...

Press Release...

        ...

Mrs Sylvia Metayer will succeed Mr Jean-Pierre Duprieu as Chair of the Clariane Board of Directors at the close of the 2025 General Meeting. At the same General Meeting, Mr Olivier Bogillot will be proposed for appointment as Independent Director. PARIS--(BUSINESS WIRE)--Regulatory News: Clariane (CLARI.PA - ISIN: FR0010386334) today announces a change in its corporate governance, with the appointment of Sylvia Metayer, an independent director, as Chairwoman of the Board of Directors at the close of the Annual General Meeting on 14 May 2025. Jean-Pierre Duprieu having indicated that he did not wish to be reappointed as Director at the Annual General Meeting of 14 May 2025, in anticipation of the statutory age limit of 75, the Board of Directors, at its meeting on 21 March 2025, chose, on the recommendation of the Compensation and Appointments Committee, Sylvia Metayer, Independent Director and member of Clariane Board of Directors since June 2024, to succeed Mr Jean-Pierre Duprieu as Chairwoman of the Boa...

Solid operating performance in 2024 Financial position strengthenedPARIS--(BUSINESS WIRE)--Regulatory News: Clariane (Paris:CLARI): Operational recovery confirmed: 2024 revenue totalled €5,282 million, up 6.6% on an organic basis, compared to an annual target of more than 5%, supported by all the Group's business segments and regions EBITDA, pre IFRS 16, excluding disposals and real-estate development activity, increased by 9.2%, corresponding to a + 30 basis point margin increase. Taking into account the impact of the real-estate development activity, EBITDA pre IFRS 16 and excluding disposals rose by +€7m, slightly ahead of the target of a stable performance in value Operating cash flow1 pre IFRS 16 was €400 million, up from €288 million in 2023, with a solid improvement in the WCR variation (€84 million) Balance sheet strengthened significantly: 2024-2025 Plan to strengthen the financial position by €1.5 billion on track: Completion of the first three parts, including €329 million of cap...